Our leadership team brings deep operating and leadership experience across all critical disciplines — science, technology, business development, marketing, people and finance — and is dedicated to building Agios into a preeminent biopharmaceutical company.
Dr. Schenkein joined Agios in August 2009 as the Chief Executive Officer and a member of our Board of Directors and has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center and is a member of the board of directors for the Biotechnology Industry Organization, the world’s largest biotechnology trade association, a position he has held since 2012. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the senior vice president, clinical hematology/oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. He currently serves on the board of directors of Foundation Medicine, Inc., bluebird bio, Inc., and Blueprint Medicines Inc. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.
Dr. Biller joined Agios as Chief Scientific Officer in September 2010, with more than 25 years of drug discovery and development experience. Most recently, from 2003 to September 2010, he was vice president and head of global discovery chemistry at the Novartis Institutes for Biomedical Research (NIBR). Prior to that, Dr. Biller held the positions of vice president, pharmaceutical candidate optimization at the Bristol Myers Squibb (BMS) Pharmaceutical Research Institute and executive director of drug discovery chemistry for the BMS research site in Lawrenceville, NJ. Among his other key leadership positions at BMS, Dr. Biller was the executive director of metabolic diseases chemistry. He contributed to robust pipelines at both BMS and Novartis, culminating in two medicines launched worldwide (Onglyza® for the treatment of Type 2 diabetes and Juxtapid® for familial hypercholestrolemia) and three additional drugs reaching Phase 3 clinical development. Dr. Biller earned a B.S. in chemistry at MIT, a Ph.D. in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University in natural product synthesis.
Mr. Higgons joined Agios in May 2009 as the Chief Operating Officer. Prior to joining Agios, Mr. Higgons worked at Archemix Corporation from 2006 to 2009 where he most recently served as president, chief operating officer and interim chief executive officer. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company which was acquired by Johnson & Johnson Company. Mr. Higgons holds a B.Sc. in mathematics from King's College University of London and an M.Sc. in economics from London Business School.
Mr. Goddard joined Agios in July 2010 as vice president, finance, and possesses more than 10 years of experience in emerging private and public platform-based biopharmaceutical companies. Prior to joining Agios, Mr. Goddard worked from 2004 to 2010 at Archemix,where he most recently served as the vice president of finance. During his time at Archemix he oversaw all aspects of financial operations. Prior to Archemix, he was the corporate controller of ImmunoGen, Inc., a publicly traded oncology-focused biopharmaceutical company. During his time at ImmunoGen, Mr. Goddard was responsible for external financial reporting, financial planning and tax compliance, and initiated the company's Sarbanes-Oxley compliance efforts. Earlier in his career, he was an audit supervisor within the Technology, Communication and Entertainment group of Ernst & Young, LLP and an audit manager at Feeley & Driscoll, P.C.. Mr. Goddard is a graduate of Bentley College, where he earned a B.S. in accountancy, and a certified public accountant in the state of Massachusetts.
Dr. Su is one of our founding scientists and has served as senior vice president, research & development since 2012. Dr. Su brings more than 20 years of organization, project management and scientific experience in the biotechnology industry to Agios. Most recently, from 2004 to 2006 he served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior to that, he spent 14 years in a number of roles, concluding his tenure as program executive and vice president of the Novartis kinase collaboration for Vertex Pharmaceuticals, a publicly-traded a pharmaceutical company. Dr. Su earned his Ph.D. in biochemistry at Duke University and was a Helen Hay Whitney Fellow at Harvard University.
Dr. Dorsch joined Agios in 2012, and most recently served at Sanofi Oncology where she headed the cancer biology group and oversaw the drug discovery efforts in Cambridge, Mass. Prior to that, she directed the research and drug discovery efforts for several oncology programs at the Novartis Institutes for Biomedical Research. Her team identified the Smoothened antagonist LDE225 (sonidegib) which is currently being evaluated in a pivotal registration trial. Prior to joining Novartis, Dr. Dorsch worked on the discovery and development of kinase inhibitors for the treatment of autoimmune diseases at Millennium Pharmaceuticals. She received her Ph.D. in biology from Free University of Berlin, Germany, and was a postdoctoral student at Columbia University in New York.
Mr. Evans joined Agios in September 2009. He possesses more than 10 years of biopharmaceuticals industry experience across a wide range of business functions. Prior to joining Agios, Mr. Evans served as director of product development at Infinity Pharmaceuticals where he led the company's most advanced oncology programs targeting Hsp90. He also established Infinity’s program management, new product planning and investor relations functions. Before Infinity, Mr. Evans held positions in the pharmaceuticals practice of McKinsey & Company, at MedImmune and at Bayer Pharmaceuticals. Mr. Evans earned an MBA in healthcare management from Wharton, a Masters in biotechnology from the University of Pennsylvania, and a B.A. in English from Yale University.
Ms. Wang joined Agios in February 2010 and has nearly 15 years of intellectual property and transactional legal experience in the biopharmaceutical industry. Prior to joining Agios, Ms. Wang served as senior patent counsel at Genentech, where she managed oncology and immunology patent portfolios, and oversaw IP aspects of potential and existing collaborations. Before Genentech, Ms. Wang served as senior patent attorney at Merck & Co. and was responsible for managing the patent portfolio around antifungal products. She was a patent agent and associate at Fish & Neave. Ms. Wang received her B.S. from Salem State College, her Ph.D. in organic chemistry from Brown University and her J.D. from the Fordham University School of Law.